News | 08 August 2012
In biotechnology, the obvious driver of stock price is the regulatory approval of drugs that ultimately become highly profitable. However, in a market where generic competition continues to increase, and wars regarding rights to drugs are constantly ...
Click on the link to read the full article at Market Playground
(This link will open in a new window)